Drug · CHEMBL20
ACETAZOLAMIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ACETAZOLAMIDE. Drugs and targets, record CHEMBL20. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL20
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Acetamox, Acetazolamida, Acetazolamidum, Atenezo, Defiltran, Didoc, Diuriwas, Donmox, Edemox, Glaupax, L 579486, NSC-145177, Nephramide, Phonurit
- ChEMBL
Targets4
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| CA1 | Carbonic anhydrase 1 | Carbonic anhydrase I inhibitor | INHIBITOR | https://conductscience.org/library/genes/759 |
| CA12 | Carbonic anhydrase 12 | Carbonic anhydrase XII inhibitor | INHIBITOR | https://conductscience.org/library/genes/771 |
| CA2 | Carbonic anhydrase 2 | Carbonic anhydrase II inhibitor | INHIBITOR | https://conductscience.org/library/genes/760 |
| CA4 | Carbonic anhydrase 4 | Carbonic anhydrase IV inhibitor | INHIBITOR | https://conductscience.org/library/genes/762 |
Source ChEMBL
Diseases49
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 49Source Open Targets
See all 49 diseasesTrials161
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03505788 | Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR) | Phase 4 | 519 | 2024-10-28 | acetazolamide | Its name | ClinicalTrials.gov |
| NCT01003639 | Idiopathic Intracranial Hypertension Treatment Trial | Phase 2/3 | 165 | 2018-12-12 | acetazolamide | Its name | ClinicalTrials.gov |
| NCT01993667 | Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing | Phase 4 | 130 | 2019-01-29 | acetazolamide | Its name | ClinicalTrials.gov |
| NCT05411991 | Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment | Phase 4 | 107 | 2025-08-08 | acetazolamide | Its name | ClinicalTrials.gov |
| NCT02604173 | Altitude Sickness Prevention and Efficacy of Comparative Treatments | Phase 3 | 103 | 2018-01-18 | acetazolamide | Its name | ClinicalTrials.gov |
| NCT01228149 | COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy | Phase 4 | 62 | 2017-04-14 | acetazolamide | Its name | ClinicalTrials.gov |
| NCT01973335 | Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure | Phase 4 | 34 | 2019-03-21 | acetazolamide | Its name | ClinicalTrials.gov |
| NCT01377987 | Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients | 29 | 2018-06-13 | acetazolamide | Its name | ClinicalTrials.gov | |
| NCT02390284 | Stop Retinal Ganglion Cell Dysfunction Study | Phase 3 | 28 | 2025-08-26 | acetazolamide | Its name | ClinicalTrials.gov |
| NCT04679389 | Acetazolamide Efficacy in Ataxia in PMM2-CDG | Phase 2/3 | 25 | 2025-03-20 | acetazolamide | Its name | ClinicalTrials.gov |
1 to 10 of 161
See all 161 trialsComparisons in its trials30
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Acetazolamide vs Placebo: Successful Decongestion | 108 of 256 | 79 of 259 | 515 | NCT03505788 | Trial comparisons |
| Acetazolamide vs Placebo: Mortality | 39 of 256 | 31 of 259 | 515 | NCT03505788 | Trial comparisons |
| Acetazolamide vs Placebo: deaths from any cause | 39 of 256 | 31 of 259 | 515 | NCT03505788 | Trial comparisons |
| Acetazolamide vs Placebo: Hospital Readmission | 47 of 256 | 45 of 259 | 515 | NCT03505788 | Trial comparisons |
| Acetazolamide vs Placebo: serious adverse events | 123 of 256 | 124 of 259 | 515 | NCT03505788 | Trial comparisons |
| Acetazolamide vs Sugar Pill: serious adverse events | 9 of 86 | 7 of 79 | 165 | NCT01003639 | Trial comparisons |
| Intervention Arm vs Control Arm: Hemodynamic Safety Endpoint | 10 of 52 | 4 of 51 | 103 | NCT05411991 | Trial comparisons |
| Intervention Arm vs Control Arm: Renal Safety Endpoint | 9 of 52 | 3 of 51 | 103 | NCT05411991 | Trial comparisons |
| Intervention Arm vs Control Arm: deaths from any cause | 3 of 52 | 4 of 51 | 103 | NCT05411991 | Trial comparisons |
| Intervention Arm vs Control Arm: serious adverse events | 6 of 52 | 14 of 51 | 103 | NCT05411991 | Trial comparisons |
1 to 10 of 30
See all 30 comparisons in its trialsPapers from its trials112
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials9
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Psychomotor Vigilance Task | 4 | 0 | ConductCognition |
| Trail Making Test A | 4 | 0 | ConductCognition |
| Trail Making Test B | 4 | 0 | ConductCognition |
| Visuomotor Adaptation Task | 2 | 1 | ConductCognition |
| Word Pair Learning | 2 | 0 | ConductCognition |
| Clock Drawing Task | 1 | 0 | ConductCognition |
| Stroop Color-Word Test | 1 | 0 | ConductCognition |
| Symbol Coding | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL20
GET https://conductscience.org/api/drugs/v1/CHEMBL20/diseases?page=2